Discover the future of biotech as startups push the boundaries of diagnostics, lab automation, analytics and drug discovery. This session will feature groundbreaking technologies transforming disease detection, laboratory sciences and the way therapies are developed. Presenters will explore innovations in single-particle dispension, real-time immunoassays, VR-powered diagnostics, next-gen allergy testing, precision medicine driven by biomarker insights, solutions advancing light-dependent biological techniques and novel approaches to accelerating drug development. Join experts and investors as they explore how these technologies are reshaping the landscape of healthcare and biotech.
May 6, 12:15-13:00, room Marriott 3+4+5
Name | Position | Institution |
---|---|---|
Samantha Paoletti | Head of Research and BD Life Science Technologies | CSEM |
Company name | Pitcher | Title of presentation | Link to company website |
---|---|---|---|
OptoLumina | Thomas Höhener, CEO of OptoLumina AG | The Lumiplate – A Multiwell Plate Lighting Device to Illuminate Biotech | https://optolumina.com/ |
Bioscibex | Chloé Albietz, CEO | Changing the way we make drugs | https://bioscibex.com/ |
SEED BIOSCIENCES | Maxence Vieux-Rochas | Accelerate time-to-market of biologics with novel impedance-based pipetting tools for precision 2D and 3D biology | https://seedbiosciences.com/ |
Atanis Biotech | Erwan Eriau, COO | Bringing Allergy diagnostics in the era of biotechnology | https://www.atanis-biotech.com/ |
Elionova | Bruno Oesch, CEO and CSO | One-step Real-time Immunoassays in 10 min: the ElioDX™ technology | https://www.elionova.com/ |
Xemperia | Sarah Cattin, CTO | A revolution in early breast cancer detection: a blood test to save lives | https://xemperia.com/ |
MachineMD | Dominic Senn, CEO | Opportunity in AI-Powered Brain Health | https://www.machinemd.com/ |
Name | Position | Institution |
---|---|---|
Bernard Spycher | Board Member | SVDI |
Miro Venturi | President | Diamante Healthcare Consulting Sagl |
Cédric Barra | Senior Investment Manager Life Sciences | OCCIDENT |
Steffen Ehrhadt | VP Investor Community, Partnerships and Sustainability | SICTIC |